Logo image of RPRX

ROYALTY PHARMA PLC- CL A (RPRX) Stock Fundamental Analysis

USA - NASDAQ:RPRX - GB00BMVP7Y09 - Common Stock

36.85 USD
+0.01 (+0.03%)
Last: 10/23/2025, 4:33:44 PM
36.85 USD
0 (0%)
After Hours: 10/23/2025, 4:33:44 PM
Fundamental Rating

5

Taking everything into account, RPRX scores 5 out of 10 in our fundamental rating. RPRX was compared to 191 industry peers in the Pharmaceuticals industry. While RPRX has a great profitability rating, there are quite some concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on RPRX.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

In the past year RPRX was profitable.
RPRX had a positive operating cash flow in the past year.
In the past 5 years RPRX has always been profitable.
RPRX had a positive operating cash flow in each of the past 5 years.
RPRX Yearly Net Income VS EBIT VS OCF VS FCFRPRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

1.2 Ratios

With an excellent Return On Assets value of 5.57%, RPRX belongs to the best of the industry, outperforming 89.53% of the companies in the same industry.
RPRX has a better Return On Equity (16.08%) than 89.53% of its industry peers.
The Return On Invested Capital of RPRX (8.50%) is better than 85.86% of its industry peers.
RPRX had an Average Return On Invested Capital over the past 3 years of 5.98%. This is significantly below the industry average of 15.45%.
The 3 year average ROIC (5.98%) for RPRX is below the current ROIC(8.50%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 5.57%
ROE 16.08%
ROIC 8.5%
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
RPRX Yearly ROA, ROE, ROICRPRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

RPRX's Profit Margin of 44.28% is amongst the best of the industry. RPRX outperforms 98.43% of its industry peers.
RPRX's Profit Margin has declined in the last couple of years.
RPRX has a Operating Margin of 79.84%. This is amongst the best in the industry. RPRX outperforms 100.00% of its industry peers.
RPRX's Operating Margin has declined in the last couple of years.
Industry RankSector Rank
OM 79.84%
PM (TTM) 44.28%
GM N/A
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
RPRX Yearly Profit, Operating, Gross MarginsRPRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 50 100

3

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so RPRX is still creating some value.
Compared to 1 year ago, RPRX has less shares outstanding
RPRX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for RPRX is higher compared to a year ago.
RPRX Yearly Shares OutstandingRPRX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M
RPRX Yearly Total Debt VS Total AssetsRPRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

RPRX has an Altman-Z score of 1.72. This is a bad value and indicates that RPRX is not financially healthy and even has some risk of bankruptcy.
RPRX has a better Altman-Z score (1.72) than 62.83% of its industry peers.
The Debt to FCF ratio of RPRX is 11.22, which is on the high side as it means it would take RPRX, 11.22 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 11.22, RPRX is in the better half of the industry, outperforming 78.53% of the companies in the same industry.
A Debt/Equity ratio of 1.10 is on the high side and indicates that RPRX has dependencies on debt financing.
With a Debt to Equity ratio value of 1.10, RPRX is not doing good in the industry: 73.82% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.1
Debt/FCF 11.22
Altman-Z 1.72
ROIC/WACC1.07
WACC7.94%
RPRX Yearly LT Debt VS Equity VS FCFRPRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B

2.3 Liquidity

A Current Ratio of 1.26 indicates that RPRX should not have too much problems paying its short term obligations.
RPRX has a worse Current ratio (1.26) than 76.44% of its industry peers.
A Quick Ratio of 1.26 indicates that RPRX should not have too much problems paying its short term obligations.
RPRX's Quick ratio of 1.26 is on the low side compared to the rest of the industry. RPRX is outperformed by 68.06% of its industry peers.
Industry RankSector Rank
Current Ratio 1.26
Quick Ratio 1.26
RPRX Yearly Current Assets VS Current LiabilitesRPRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 1.80% over the past year.
The earnings per share for RPRX have been decreasing by -18.23% on average. This is quite bad
Looking at the last year, RPRX shows a small growth in Revenue. The Revenue has grown by 3.02% in the last year.
RPRX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.52% yearly.
EPS 1Y (TTM)1.8%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%18.75%
Revenue 1Y (TTM)3.02%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%19.57%

3.2 Future

RPRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.50% yearly.
Based on estimates for the next years, RPRX will show a quite strong growth in Revenue. The Revenue will grow by 11.13% on average per year.
EPS Next Y11.99%
EPS Next 2Y11.77%
EPS Next 3Y11.6%
EPS Next 5Y13.5%
Revenue Next Year14.1%
Revenue Next 2Y7.48%
Revenue Next 3Y7.67%
Revenue Next 5Y11.13%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RPRX Yearly Revenue VS EstimatesRPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B 5B
RPRX Yearly EPS VS EstimatesRPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2 4 6 8

8

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 9.33, the valuation of RPRX can be described as very reasonable.
RPRX's Price/Earnings ratio is rather cheap when compared to the industry. RPRX is cheaper than 91.10% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.67, RPRX is valued rather cheaply.
A Price/Forward Earnings ratio of 7.20 indicates a rather cheap valuation of RPRX.
Based on the Price/Forward Earnings ratio, RPRX is valued cheaper than 90.05% of the companies in the same industry.
RPRX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.33.
Industry RankSector Rank
PE 9.33
Fwd PE 7.2
RPRX Price Earnings VS Forward Price EarningsRPRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, RPRX is valued cheaply inside the industry as 80.10% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 30.14
EV/EBITDA N/A
RPRX Per share dataRPRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

RPRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
RPRX has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.78
PEG (5Y)N/A
EPS Next 2Y11.77%
EPS Next 3Y11.6%

5

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 2.42%, RPRX has a reasonable but not impressive dividend return.
RPRX's Dividend Yield is rather good when compared to the industry average which is at 6.88. RPRX pays more dividend than 93.19% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.35, RPRX has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 2.42%

5.2 History

RPRX has been paying a dividend for over 5 years, so it has already some track record.
RPRX has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years4
Div Non Decr Years4
RPRX Yearly Dividends per shareRPRX Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8

5.3 Sustainability

36.87% of the earnings are spent on dividend by RPRX. This is a low number and sustainable payout ratio.
DP36.87%
EPS Next 2Y11.77%
EPS Next 3Y11.6%
RPRX Yearly Income VS Free CF VS DividendRPRX Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B
RPRX Dividend Payout.RPRX Dividend Payout, showing the Payout Ratio.RPRX Dividend Payout.PayoutRetained Earnings

ROYALTY PHARMA PLC- CL A

NASDAQ:RPRX (10/23/2025, 4:33:44 PM)

After market: 36.85 0 (0%)

36.85

+0.01 (+0.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners82.15%
Inst Owner Change0.15%
Ins Owners1.79%
Ins Owner Change52.46%
Market Cap21.49B
Revenue(TTM)2.31B
Net Income(TTM)1.02B
Analysts81.43
Price Target44.31 (20.24%)
Short Float %5.41%
Short Ratio5.03
Dividend
Industry RankSector Rank
Dividend Yield 2.42%
Yearly Dividend0.63
Dividend Growth(5Y)N/A
DP36.87%
Div Incr Years4
Div Non Decr Years4
Ex-Date08-15 2025-08-15 (0.22)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-28.44%
Min EPS beat(2)-59.9%
Max EPS beat(2)3.01%
EPS beat(4)3
Avg EPS beat(4)-10.84%
Min EPS beat(4)-59.9%
Max EPS beat(4)6.88%
EPS beat(8)5
Avg EPS beat(8)-4.24%
EPS beat(12)8
Avg EPS beat(12)-0.53%
EPS beat(16)9
Avg EPS beat(16)-6.35%
Revenue beat(2)2
Avg Revenue beat(2)6.9%
Min Revenue beat(2)4.2%
Max Revenue beat(2)9.61%
Revenue beat(4)2
Avg Revenue beat(4)-5.21%
Min Revenue beat(4)-20.42%
Max Revenue beat(4)9.61%
Revenue beat(8)2
Avg Revenue beat(8)-9.06%
Revenue beat(12)2
Avg Revenue beat(12)-11.79%
Revenue beat(16)4
Avg Revenue beat(16)-9.44%
PT rev (1m)0.39%
PT rev (3m)4.83%
EPS NQ rev (1m)0.16%
EPS NQ rev (3m)-2.95%
EPS NY rev (1m)0%
EPS NY rev (3m)5.08%
Revenue NQ rev (1m)0.7%
Revenue NQ rev (3m)-1.33%
Revenue NY rev (1m)0.1%
Revenue NY rev (3m)4.47%
Valuation
Industry RankSector Rank
PE 9.33
Fwd PE 7.2
P/S 9.32
P/FCF 30.14
P/OCF 8.93
P/B 3.39
P/tB 3.96
EV/EBITDA N/A
EPS(TTM)3.95
EY10.72%
EPS(NY)5.12
Fwd EY13.9%
FCF(TTM)1.22
FCFY3.32%
OCF(TTM)4.13
OCFY11.2%
SpS3.95
BVpS10.89
TBVpS9.3
PEG (NY)0.78
PEG (5Y)N/A
Graham Number31.1
Profitability
Industry RankSector Rank
ROA 5.57%
ROE 16.08%
ROCE 10.75%
ROIC 8.5%
ROICexc 9.3%
ROICexgc 9.89%
OM 79.84%
PM (TTM) 44.28%
GM N/A
FCFM 30.93%
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
ROICexc(3y)6.7%
ROICexc(5y)7.58%
ROICexgc(3y)6.7%
ROICexgc(5y)7.59%
ROCE(3y)7.57%
ROCE(5y)8.31%
ROICexgc growth 3Y-4.76%
ROICexgc growth 5Y-18.24%
ROICexc growth 3Y-4.74%
ROICexc growth 5Y-18.16%
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 1.1
Debt/FCF 11.22
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 73.45%
Interest Coverage -8.39
Cash Conversion N/A
Profit Quality 69.86%
Current Ratio 1.26
Quick Ratio 1.26
Altman-Z 1.72
F-Score7
WACC7.94%
ROIC/WACC1.07
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)92.8%
Cap/Sales(5y)95.39%
Profit Quality(3y)349.23%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.8%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%18.75%
EPS Next Y11.99%
EPS Next 2Y11.77%
EPS Next 3Y11.6%
EPS Next 5Y13.5%
Revenue 1Y (TTM)3.02%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%19.57%
Revenue Next Year14.1%
Revenue Next 2Y7.48%
Revenue Next 3Y7.67%
Revenue Next 5Y11.13%
EBIT growth 1Y91.7%
EBIT growth 3Y-3.33%
EBIT growth 5Y-13.2%
EBIT Next Year28.89%
EBIT Next 3Y14.6%
EBIT Next 5Y13.78%
FCF growth 1Y36.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.52%
OCF growth 3Y11.13%
OCF growth 5Y10.68%